Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTX-4975 in Morton's Neuroma
NCT02550756Phase 1Completed
- Sponsor
- Centrexion Therapeutics
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of capsaicin in Morton's neuroma, sponsored by Centrexion Therapeutics. Primary endpoints: Incidence, intensity, relationship and seriousness of treatment-emergent adverse events at 6 months, Treatment-emergent changes in vital signs and laboratory tests at 2 weeks and 2 more. Started Feb 2014; status: completed.
02
Drugs
capsaicin
03
Conditions
Morton's neuroma
Beyond the preview
Go deeper on NCT02550756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550756.